Tirzepatide vs. Retatrutide: Dual vs. Triple Agonist Explained
Tirzepatide is a dual agonist: it activates the GIP and GLP-1 receptors. Retatrutide is a triple agonist: it activates those two receptors and adds the glucagon receptor. According to Eli Lilly’s medical information page, that extra receptor is the defining difference between the two molecules. The other differences follow from it: how far each has progressed through clinical development, what the trials report, and what researchers should know about each compound. This guide walks through all of it in plain language for researchers, clinic staff and informed readers.
TL;DR
- Tirzepatide is a dual GIP/GLP-1 receptor agonist. It is FDA-approved as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management and obstructive sleep apnea in adults with obesity).
- Retatrutide is a single molecule that targets GIP, GLP-1 and glucagon receptors. It remains investigational and is not approved by the FDA or any other regulator.
- Both are designed for once-weekly subcutaneous dosing, with half-lives of roughly 5 days (tirzepatide) and 6 days (retatrutide, Phase 1).
- Published retatrutide trial data show large weight reductions, but comparisons across separate trials need care, and gastrointestinal side effects are the most common reason for discontinuation.
- Compounds supplied by Peppy&Me are for laboratory research use only, and every lot is third-party tested with a traceable certificate of analysis (COA).
What “agonist” means, and why the count of receptors matters
An agonist is a molecule that binds a receptor and switches it on. Tirzepatide and retatrutide are both peptides built to mimic natural gut and pancreatic hormones (incretins and related signals) that help regulate appetite, insulin release and energy use.
A single agonist, such as a GLP-1 receptor agonist, engages one pathway. A dual agonist engages two. A triple agonist engages three, with one molecule doing the work that would otherwise need several. One academic perspective on incretin-based therapies notes that their effectiveness depends in part on long duration of action and continuous receptor activation, which keeps appetite-suppressing signals active across the whole dosing interval.
The reasoning behind multi-receptor design is that each hormone contributes something different. A review of triple agonism for obesity describes these agents as being developed to improve weight loss and metabolic outcomes by engaging several hormonal pathways at once. That is a design rationale, not a guarantee of any result in a given study system.
The three receptors, one by one
GLP-1: appetite and glucose
The glucagon-like peptide-1 (GLP-1) receptor is the best-known target. Activating it supports glucose-dependent insulin secretion and acts on appetite and satiety signaling in the brain. Both tirzepatide and retatrutide engage it.
GIP: the second incretin
The glucose-dependent insulinotropic polypeptide (GIP) receptor is the second incretin target. Tirzepatide’s defining feature, compared with earlier single-target compounds, is that it adds GIP activity to GLP-1 activity. Retatrutide keeps both.
Glucagon: the added layer
Glucagon is usually described as the counterpart of insulin, raising blood glucose when needed. In the context of weight research, interest in glucagon receptor activation centers on energy expenditure and liver fat metabolism. Retatrutide is the molecule that adds this receptor on top of GLP-1 and GIP. Because glucagon receptor activity is the new element, it is also the focus of much of the ongoing safety and dose-response work.
Side-by-side comparison
| Feature | Tirzepatide | Retatrutide |
|---|---|---|
| Receptor targets | GIP and GLP-1 | GIP, GLP-1 and glucagon |
| Classification | Dual agonist | Triple agonist |
| Regulatory status (U.S.) | FDA-approved as Mounjaro and Zepbound | Investigational, not approved |
| Route | Subcutaneous injection | Subcutaneous injection (studied) |
| Dosing interval | Once weekly | Once weekly (studied) |
| Half-life | About 5 days | About 6 days (Phase 1 study) |
The receptor targets, route and half-life figures above come from Lilly’s comparison of the two molecules. The approved indications are summarized in a professional side-by-side of the two tirzepatide brands.
What the clinical data show
Tirzepatide: an approved, well-characterized dual agonist
Tirzepatide is FDA-approved as Mounjaro for type 2 diabetes and as Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Per Lilly’s product page, Mounjaro is supplied in prefilled single-dose pens in strengths from 2.5 mg to 15 mg per 0.5 mL injection. Maintenance doses include 5 mg, 10 mg or 15 mg weekly, as listed in the side-by-side comparison.
Retatrutide: promising but still in trials
In the Phase 2 obesity trial published in the New England Journal of Medicine, participants on the highest retatrutide dose (12 mg) lost a mean of about 24% of body weight at 48 weeks. The full report, Triple-Hormone-Receptor Agonist Retatrutide for Obesity, gives the dose groups and methods. In the Phase 2 study in type 2 diabetes, retatrutide improved HbA1c by 2.2%.
A network meta-analysis found greater absolute and percentage weight reduction with retatrutide than with tirzepatide. That finding is useful for framing hypotheses. It is still an indirect comparison across separate trials with different populations, durations and designs, so it does not replace a head-to-head study.
Reading the numbers responsibly
When comparing figures from different studies, check four things:
- Population. Adults with obesity alone and adults with obesity and type 2 diabetes typically show different average weight loss.
- Duration. A 48-week result and a 72-week result are not interchangeable.
- Dose. Results are reported per dose group, and the highest dose is not representative of the whole trial.
- Trial phase. Phase 2 results are exploratory. Phase 3 results are designed to support regulatory submissions.
Safety and tolerability
Both molecules share a class pattern: gastrointestinal effects are the most common. In the retatrutide Phase 2 obesity trial, any adverse event occurred in 73% to 94% of participants across dose groups. Discontinuation because of adverse events ranged from 6% to 16%, and gastrointestinal events were the most common cause.
Two points deserve attention from anyone reading this literature:
- Safety and efficacy data for retatrutide are still being collected across a large Phase 3 program.
- Dose escalation is a central part of how these molecules are studied, because tolerability depends on how gradually exposure increases.
Regulatory status: why one is approved and the other is not
Per Lilly’s retatrutide FAQ, last updated September 2026, retatrutide is investigational, is not approved by the FDA or any regulatory agency, is not available for public use, and is legally available only to participants in Lilly-sponsored clinical trials. The same page lists Phase 3 programs studying once-weekly subcutaneous retatrutide in obesity, type 2 diabetes, knee osteoarthritis pain, moderate-to-severe obstructive sleep apnea, chronic low-back pain, cardiovascular and renal outcomes, and metabolic dysfunction-associated steatotic liver disease.
It helps to understand what “not approved” does and does not mean. FDA approval requires a very large financial investment, multi-phase clinical trials and substantial commercial backing. Compounds that are naturally occurring or hard to patent often attract less of that funding, even when scientific interest in them continues. Many research peptides sit in that space. Lack of approval reflects where funding and development have gone, and it is not a verdict on laboratory interest in a molecule.
For retatrutide specifically, the lack of approval means it is in the late stages of a formal development path. Lilly also states that its safety perspective is that people should receive retatrutide only in a clinical trial setting, because unregulated products cannot be verified for identity, purity or dose. That statement is the reason documentation matters so much for laboratory work, as discussed below.
Administration and dosing in the literature
Both compounds are studied as once-weekly subcutaneous injections. The long half-life, about 5 days for tirzepatide and about 6 days for retatrutide in a Phase 1 study, is what makes weekly intervals pharmacologically sensible.
The questions people ask about route (for example, whether an oral form of tirzepatide performs the same as the injectable) cannot be answered from approved labeling, because the approved forms are injections. Researchers handling lyophilized material in the lab should rely on documented protocols, correct reconstitution and proper storage rather than informal guidance. The Peppy&Me peptide glossary and built-in dose calculator are designed to support exactly this kind of measurement and handling work for research purposes.
Dual or triple: which question is the research actually asking?
The two compounds answer different research questions.
- Tirzepatide is the established reference point. It is useful for studying GIP and GLP-1 co-agonism with a large body of published, approved-drug data behind it. For background on how the compound relates to its branded forms, see this guide to tirzepatide for researchers.
- Retatrutide is the frontier compound. It is used to study what happens when glucagon receptor activity is layered onto GIP and GLP-1 signaling. A deeper look at the third target is in our explainer on retatrutide’s three receptors, and a direct contrast with dual agonists is in this retatrutide versus dual agonists guide.
A common point of confusion is the nickname “GLP-3.” No such receptor exists, and retatrutide does not target a third GLP receptor. Its third target is the glucagon receptor.
Verifying research material: what the documentation should show
Because identity, purity and dose cannot be assumed for unregulated material, a lot-specific COA is the baseline for any research use. Documentation worth checking includes:
- Purity by chromatography for the specific lot.
- Mass accuracy, confirming the compound is what the label says.
- Endotoxin results, relevant for any cell-based or in vivo research system.
- Sterility testing.
- Heavy metals analysis.
- Traceable lot and batch numbers that connect the vial to the report.
For a practical walk-through of reading these reports across three related compounds, see this guide to verifying COAs for semaglutide, tirzepatide and retatrutide.
Our perspective
We built Peppy&Me around a simple observation: the more interesting a compound becomes, the more the quality of the material matters. Dual and triple agonist research moves quickly, and results are only as meaningful as the identity and purity of what went into the experiment.
That is why every lot we supply is independently third-party tested for purity, mass accuracy, endotoxins, sterility and heavy metals, with lot and batch numbers traceable from manufacturer to warehouse and COA access through a QR code. We believe researchers should be able to see that documentation before they work with a compound, not after.
We also believe good research support goes beyond the vial. Our peptide glossary and dose calculator are there so that handling, reconstitution and measurement questions have a clear, documented answer. Everything we supply is for laboratory research use only, and we keep our language, our labeling and our compliance to that standard.
Peppy&Me
Research materials from Peppy&Me
Researchers studying dual and triple agonism can find both compounds in the catalog: Tirzepatide and Retatrutide, supplied for laboratory research use only to authorized individuals aged 21 and over. Orders placed before 2 PM ship the same day within the U.S., and each lot comes with third-party testing documentation.
To browse the full range, including amino acids, derivatives and blended research materials, visit the research compounds catalog.
FAQ
What is the main difference between tirzepatide and retatrutide?
Tirzepatide activates two receptors, GIP and GLP-1. Retatrutide activates those two and also the glucagon receptor. Tirzepatide is FDA-approved, while retatrutide is still investigational and in Phase 3 development.
What receptors does retatrutide target?
Retatrutide is a single molecule that acts on the GIP, GLP-1 and glucagon receptors. This is why it is called a triple agonist. It is sometimes nicknamed “GLP-3”, but that is not a real receptor, and the third target is glucagon.
Is retatrutide FDA-approved?
No. Per Lilly’s September 2026 FAQ, retatrutide is investigational and not approved by the FDA or any regulator. It is legally available only to participants in Lilly-sponsored clinical trials.
How are the two compounds administered in studies?
Both are studied as once-weekly subcutaneous injections. Lilly’s comparison page gives tirzepatide a half-life of about 5 days and retatrutide about 6 days in a Phase 1 study, which supports weekly intervals.
Does more receptors always mean better results?
Not necessarily. A triple mechanism gives researchers more pathways to study, and trial data on retatrutide are encouraging. But cross-trial comparisons are indirect, and tolerability, dose escalation and long-term safety are still being evaluated in Phase 3 work.
Sources
- What is the difference between the retatrutide and tirzepatide molecules? (Eli Lilly medical information)
- What to know about retatrutide (Eli Lilly)
- Mounjaro and Zepbound product information (Eli Lilly)
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity (NEJM)
- Triple Agonism Based Therapies for Obesity (PMC)
- Comparative Efficacy and Safety of Tirzepatide vs. Retatrutide (PMC)
- How should we think about the unprecedented weight loss with incretin mimetics? (PMC)
- Mounjaro vs Zepbound: Side-by-Side Comparison